Supriya Lifescience Limited has informed the Exchange about Investor Presentation
May 27, 2025
To,
BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434
Dear Sir/Madam,
Subject: Investor Presentation.
National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
Further to our Letter dated may 21, 2025, we are enclosing herewith Investor Presentation with respect to Audited Financial Results of the Company for the quarter ended on March 31, 2025.
Kindly take the information on record.
Thanking you,
For Supriya Lifescience Limited
Prachi Sathe Company Secretary & Compliance Officer
Corporate office
: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX Tel: +91 22 40332727 / 66942507
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE
SUPRIYA LIFESCIENCE LTD.
Investor Presentation | Q4 & FY25
Safe Harbour
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information
purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any
contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information
about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express
or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not
be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly
excluded
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-
looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are
difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the
performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion,
technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other
risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The
Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included
in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
Q4 FY25 Earnings Presentation
2
Q4 & FY25 Highlights
Q4 FY25 Highlights
y l r e t r a u Q
e c n a m r o f r e P
l
a n o i g e R
Revenue
EBITDA
PBT
PAT
INR 1841.1 Mn
INR 675.8 Mn
INR 640.6 Mn
INR 503.8 Mn
16% YoY
22% YoY
20% YoY
38% YoY
Business Mix Revenue Contribution – By Region
35%
31%
30%
43%
40%
36%
26%
21%
11%
6%
3%
2%
5%
5%
6%
Asia
Europe
LATAM
North America
Others
Q4 FY25 Earnings Presentation
Q4 FY24
Q3 FY25
Q4 FY25
4
FY25 Highlights
y l r a e Y
e c n a m r o f r e P
l
a n o i g e R
Revenue
EBITDA
PBT
PAT
INR 6,964.9 Mn
INR 2,608.0 Mn
INR 2,484.8 Mn
INR 1,879.6 Mn
22% YoY
51% YoY
50% YoY
58% YoY
Business Mix Revenue Contribution – By Region
38%
33%
41%
37%
22%
11%
6%
3%
4%
5%
Asia
Europe
LATAM
North America
Others
Q4 FY25 Earnings Presentation
FY24
FY25
5
Q4 & FY25 - Y-o-Y Highlights
Revenue
EBITDA
PBT
PAT
(in INR Mn)
+22%
+51%
6964.8
5703.7
+16%
2608
+22%
1729.8
+50%
2484.8
+58%
1879.6
1656.9
+20%
1191.1
+38%
1581.8
1841.1
555
675.8
531.8
640.6
364
503.8
FY24
FY25
Q4FY24 Q4FY25
FY24
FY25
Q4FY24 Q4FY25
FY24
FY25
Q4FY24 Q4FY25
FY24
FY25
Q4FY24 Q4FY25
EBITDA Margins
PAT Margins
+712 bps
+162 bps
37%
35%
37%
30%
+610 bps
+435 bps
27%
27%
23%
21%
Q3 FY25 Earnings Presentation
6
FY24
FY25
Q4FY24 Q4FY25
FY24
FY25
Q4FY24 Q4FY25
Business Mix Revenue Contribution – By Therapy
Performance of the Top Therapeutic Areas
49%
42%
15%
11%
13%
11%
8%
3%
7%
7%
5%
4%
2%
3%
Anesthetic
Analgesic
Anti-Histamine
Vitamins
Anti-Asthmatic
Anti-Allergic
Anti-hypertensive
FY24
FY25
Q4 FY25 Earnings Presentation
7
Profit & Loss Statement
Particulars (in INR Mn)
Revenue from Operations
Cost of Goods Sold
Employee Benefits Expense
Other Expenses
EBITDA
EBITDA %
Other Income
Depreciation and Amortisation Expense
EBIT
Finance Costs
PBT
Total Tax Expense
Profit for the year
PAT %
EPS (INR)
Q4 FY25 Earnings Presentation
Q4 FY25
Q4 FY24
Y-o-Y
Q3 FY25
Q-o-Q
FY25
FY24
1,841.1
1,581.8
548.3
209.8
407.2
675.8
582.6
171.4
272.7
555.0
16.4%
-5.9%
22.4%
49.3%
21.8%
1,856.5
-0.8%
6,964.8
5,703.4
617.8
197.7
381.4
659.5
-11.3%
2,111.8
2,217.4
6.1%
6.8%
2.5%
805.2
676.4
1,439.9
1,079.9
2,608.0
1,729.8
Y-o-Y
22.1%
-4.8%
19.0%
33.3%
50.8%
36.7%
35.1%
+162 bps
35.5%
+118 bps
37.4%
30.3%
+712 bps
29.7
60.8
21.9
39.1
644.8
537.8
4.2
640.6
136.8
503.8
6.0
531.8
162.4
369.3
36.1%
55.4%
19.9%
-30.4%
20.5%
-18.5%
38.4%
21.0
49.6
630.9
5.1
625.8
158.0
467.8
41.8%
22.5%
2.2%
98.1
204.4
106.4
158.1
2,501.7
1,678.0
-7.7%
29.3%
49.1%
-17.5%
16.9
21.1
-20.1%
2.4%
2,484.8
1,656.9
-13.4%
605.2
465.8
7.7%
1,879.6
1,191.1
50.0%
29.9%
57.8%
27.4%
23.0%
+435 bps
25.2%
+217 bps
27.0%
20.9%
+610 bps
6.29
4.59
5.82
23.35
14.80
8
Balance Sheet
Assets
Non-current assets (i) Property, plant and equipment (ii) Right to Use Asset (iii)Capital Work in progress (iv) Intangible Assets (v) Financial Assets -Investments -Loans and Advances (vi) Other Non- Current Assets Total Non-current assets
Current assets (i) Inventories (ii) Financial Assets -Trade receivables -Cash and cash equivalents -Bank balances other than above -Other financial Assets -Loans and Advances (iii) Other current assets Total Current Assets TOTAL ASSETS
Q4 FY25 Earnings Presentation
FY24
FY25
Equity and Liabilities
3,037 48 1,488 17
638 - 7 5,234
4,468 46 1,480 14
632 - 112 6,753
852
1,183
1,117 750 - 45 7 1,207 3,978 9212
1,344 761 31 7 9 1,035 4,370 11,123
Equity (i) Equity share capital (ii) Other equity Total Equity Non-current liabilities (i) Financial Liabilities -Borrowings -Lease Liabilities -Other financial liabilities (ii) Provisions (iii) Deferred tax Liabilities Total Non-Current Liabilities Current liabilities (i) Financial liabilities -Borrowings -Lease Liabilities -Trade payables -Other financial liabilities (iii) Provisions (ii) Other current liabilities Total Current Liabilities TOTAL EQUITY AND LIABILITIES
FY24
161 7,993 8,154
- 50 - 8 232 290
5 596 16 4 149 769 9,212
(in INR Mn) FY25
161 9,807 9,968
- 51 - 13 270 334
3 745 18 12 43 822 11,123
9
Company Overview
Business Overview
Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics
40+ APIs
120+ Countries
33,000 Sq.mts
932 KLPD
Niche product basket
Diversified operations with presence
Manufacturing facility spread across
Reactor capacity
WHO-GMP, Written Confirmation, ISO, Halal, Indonesian Halal. Fami QS
18
DMFs with USFDA
10
CEP granted
1,500+
customers
3 Times USFDA approved
2 times EUGMP/EDQM approved
HEALTH CANADA
COFEPRIS
ANVISA
KFDA
NMPA
TGA
AIFA
Q4 FY25 Earnings Presentation
11
Journey So Far
2020
2021
2022
2023
2024
Third time USFDA approval
CEP granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate; NMPA approval granted; Health Canada approval
Listed on Stock Exchange BSE & NSE
CEP (Certificate of suitability ) renewed for Pheniramine Maleate, Chlorpheniramine Maleate and Ketamine Hydrochloride
The Company commenced operations at its new R&D lab in Lote Parshuram
ANVISA Approval Granted
2018
2017
2015
2014
2013
CEP granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride
CEP granted for Pheniramine Maleate; Second time USFDA approval granted
EUGMP and EDQM approval granted
USFDA approval granted; IDL granted for Brompheniramine Maleate
COFEPRIS and KFDA approval granted
2008
2009
2010
2011
Incorporation & conversion from a partnership firm to a public limited company
Started production of Ketamine hydrochloride
CEP granted for Chlorphenamine Maleate
IDL granted for Chlorphenamine Maleate
12
Q4 FY25 Earnings Presentation
Backward Integrated Business Model
Supply Security
Low Price Risk
In-House Processes
Steady supply of essential raw materials
Protection against market fluctuations
Less Dependence On External Parties
Cost-competitive Structure
Increasing margins
18 products are backward integrated* in following therapies
Anesthetics
Anti-Asthmatic
Anti-Histamine
Decongestant
Anti-Gout
72%
of FY25 revenue
Integrated business model helped us grow revenue and sustain margins in the last year. Large part of growth and sustainability was driven by these backward integrated products
Note: In the process of further backward integrating 3 more products
Q4 FY25 Earnings Presentation
* As on 31st March 2025
13
Diversified Geographic Presence
New Therapies Launched
• Contrast Media • Cardio Vascular • ADHD
Presence in 86+ Countries Across Globe
Q4 FY25 Earnings Presentation
14
Diversified Revenues with Extensive Global Presence
Significant export presence, with low dependence on a specific geography
… with balanced customer concentration
Export sales, as a % of revenue from operations
Share of top 10 customers, as a % of revenue from operations
77%
76%
80%
79%
85%
40%
47%
45%
49%
58%
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Long standing relationship with global pharma companies …
… We plan to further reduce customer concentration
Penetration of existing products to newer geographies by registering these products
Adding new niche products with high volume potential for which we are building 2 new R&D centers
CMO/CDMO opportunities
Q4 FY25 Earnings Presentation
15
Advanced Manufacturing
o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, for engineering maintenance, dedicated areas warehouse, raw materials, packaging materials and finished goods stores
o Recently commissioned Effluent treatment plant for future volume growth and express feeder from the sub-station to ensure reliable power supply
o Commissioned new warehouses and administration block, with new Quality Control Labs, Quality Assurance and R&D Labs (IGBC Gold Certified)
o Strategic Land Acquisitions: ➢ 12,551 sq.mt.: Adjacent to the existing facility to enable seamless future growth and expansion ➢ 24,646 sq.mt.: Located 20 km from the current for backward
strategically acquired facility, integration to enhance operational efficiency ➢ 80,000 sq.mt.: Situated at Isambe, Patalganga, near the upcoming Navi Mumbai International Airport.
Q4 FY25 Earnings Presentation
5 Manufacturing Blocks
9 Clean Rooms
932 KLPD Reactor Capacity
33,000sq.mt. Land Area
Scaled up Manufacturing Facilities over the years
Healthy capacity utilization
Block A
Block B
Block C
Block D
Block E
Ramp up of production from Module E will drive the capacity utilisation
Year of Establishment
1993
1994
2014
2021
2024
71%
70%
70%
86%
Capacities
157 KLPD 195 KLPD 30 KLPD 215 KLPD 335 KLPD
47%
Regulatory Approved
✓
✓
✓
✓
✓
FY21
FY22
FY23
FY24
FY25
16
R&D Capabilities
y t i l i c a f d e v o r p p a R I S D
18* DMFs
4* Process Patent Filed in India
10* CEPs
10* CADIFA Brazil
Supported by R&D driven mindset
• A team of 60+ scientists primarily focused on API process development across the value chain
• Already started two R&D centres –
o Ambernath R&D – for formulations and o Lote R&D – Generic APIs & Lifecycle improvement
• Consistent efforts to develop new products, improve existing formulations, enhance drug delivery
systems, and expand product applications.
Q4 FY25 Earnings Presentation
* As of March 2025
17
CMO Capabilities
• State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation
• Complete support in validation, stability, & compilation of dossiers
• Dedicated technology transfer team is periodically trained to enhance skills for timely scale-ups and validations
•
\
• Quality & regulatory team is well trained with latest guidelines to ensure on-time dossier submissions.
Q4 FY25 Earnings Presentation
18
Recently Commissioned state-of-the-art E Block
• Capacity: 335 KLPD
• Large volume equipment – multipurpose synthesis with focus on
backward integration capabilities
• Closed systems using gravity flow equipped with process control
system.
Q4 FY25 Earnings Presentation
19
FDF Facility ready for commissioning at Ambernath
Facility Location
• The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60,
Additional Ambernath MIDC, District Thane, Maharashtra,
• Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International Airport.
R&D
• Dosage forms R&D being set up for tablets, capsules, liquids, sterile forms • Analytical laboratories & Complex API synthesis facilities alongside dosage forms
development for efficiency
• Focus areas – complex forms, anti-diabetics, anesthetics.
Manufacturing
• FDF facilities to commission from Q2FY26 • Tablets, capsules and liquids • Large volume liquids filling line • Validation and registration batches for dossier submissions.
Q4 FY25 Earnings Presentation
20
Complex Chemistries & Reaction
Focus on uniform manufacturing standards to achieve standardised product quality across markets
Ability to handle complex chemistries..
•
•
•
•
Simple to highly complex chiral molecules
Controlled substances
Products with specialized environment for manufacturing (Methylcobalamin, Vitamin B12 & derivatives)
Precision distillation of volatile inhaled Anesthetic APIs yielding high purity > 99.97%.
s n o i t c a e r f o s s a l c d e i r a v s s o r c a …
Cyclisation
High vacuum distillations Grignard reaction Fridel craft acylation
Decyanation
Etherification
High pressure catalytic reductions
Formylation Bromination Oxirane
Nitration
Lithiation
Q4 FY25 Earnings Presentation
21
Regulatory Achievements
Strong focus on compliance guided by ethical approach
• Our motto
is to consistently meet the stringent requirements of
regulatory bodies
• Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries from both authorities and customers.
50+
Registrations in different countries
10+
CEP’s
Q4 FY25 Earnings Presentation
500+
Customer Audit Approvals
15+
USDMF’s
22
Regulatory Approvals
USDMF
CEP
CADIFA Brazil
KDMF Korea
NMPA China
18
10
10
5
3
Q4 FY25 Earnings Presentation
23
Awards & Accreditation
2009
Certificate of Excellence outstanding Export Performance in the product group Chemicals, Drugs, (MSME) awarded by Pharma and Allied Products Federation of Indian Export Organisation
for
2017
2019
2010
2016
Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India
Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra Export Achievement for 2015-16 in the product group Basic Products (MSME) Chemical, awarded by Government of Maharashtra
Pharmaceutical & Cosmetics
Directorate of
Industries,
Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra Export Achievement for 2016-17 in the product & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra
Chemical
group
Basic
Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of Indi
Q4 FY25 Earnings Presentation
24
Key Management Team
Satish Wagh Executive Chairman & WTD • An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University. • B.Sc. from R.D National College and W.A. Science College, University of Bombay. • Director on the board of Supriya Medi-Chem Private Limited, Lote Industries Testing Laboratory Association and Sachin Industries Limited.
Saloni Wagh Managing Director • Ph.D. in chemistry from the Faculty of Science, Pacific University, Udaipur. • M.Sc. from Institute of Science, University of Mumbai. • B.Sc. from Parle Tilak Vidhyalaya Association’s Sathaye College, University of Mumbai.
Shivani Wagh Joint Managing Director • Master’s degree in International business management from Manchester Business School, University of Manchester. • Bachelor’s degree in management studies from M.L. Dahanukar College of Commerce, University of Mumbai.
Krishna Raghunathan Chief Financial Officer • Chartered Accountant (CA) from ICAI • Bachelor degree of Science in Zoology from Madras University. • Previously associated with companies like Dr. Reddy’s Laboratories Limited and Granules India Limited.
Q4 FY25 Earnings Presentation
25
EHS
Environment
Health
Safety
• Regular and strict monitoring to produce highest
• Clean, safe and healthy working environment for our
• Committed to safe and accident-free operations in all
efficiency in pollution control
all employees
• Mandatory medical examination and periodic
medical checkup
• Regular training workshops for employees involved in handling materials, operating various process, waste generation and treatment.
• Commitment to reduce, recycle and reuse all resources for conservation and waste reduction, wherever feasible
• Own ETP facility – 400 KLPD, 2000 KL retention
volume
• CETP membership – additional discharge of 260 KLPD • Over the years about 56% reduction in cost reduction
and relevant oil consumption
• Focus on solvent recovery, reduced emissions
• Adoption of paperless culture since 2015
•
Implementation of ERP system has drastically reduced use of overall paper.
Q4 FY25 Earnings Presentation
our establishments
• Safeguarding our employees and
acquiring the knowledge of hazardous activities carried out in the neighborhood
facilities by industrial
• Frequent fire safety mock drills and intensive training safety awareness and
inculcate
programs to adherence to safety policies
• Periodic internal and external audit for ensuring
•
compliance to our safety policy. Implementation of closed-system pneumatic transfer systems for material handling, replacement of liquid bromine with safer alternatives, establishment of a robust work permit system, and deployment of process control systems to monitor safety-critical parameters.
26
CSR & Social Work
We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm
• Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the students in the nearby schools to promote education
Supporting and participating with NGOs in chosen fields
• • Utilization of CSR funding for drinking water scarcity in villages near
our factory site
• Contribution to Prime Minister National Relief Fund •
Support patients for cancer treatment
•
Fund raisers and donations to worthy social causes, etc.
Q4 FY25 Earnings Presentation
27
Historical Financial Performance
Consistent & Strong Financial Performance
Robust revenue growth
Capex Spend
… and, focus on profitability
(in INR Mn)
15.5%
5,301
4,609
5,703
3,912
6,965
1,457
1,623
949
1,078
2,140
1,518
1,732
1,236
2,608
1,880
1,880
1,289
899
1,191
94
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23 EBITDA
FY24
FY25
PAT
Return on Net Worth
Healthy leverage profile
46.0%
0.26
24.7%
12.9%
15.0%
18.9%
0.04
0.03
0.01
0.01
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Q4 FY25 Earnings Presentation
29
Working Capital Break-up
Inventory
Receivables
206
233
172
165
198
73
71
72
63
61
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Payables
Net Working Capital
75
59
49
113
112
194
196
235
158
124
FY21
FY22
FY23
FY24
FY25
FY21
FY22
FY23
FY24
FY25
Q4 FY25 Earnings Presentation
30
Future Outlook
Future Outlook
Two new R&D centres
CMO/CDMO space
• The future of the company is deeply rooted in R&D, with significant progress made to
• Company understands large scale special chemical manufacturing and has experience in
enhance research capabilities
handling hazardous complex process chemistry
1. The R&D lab at Lote Parshuram spans 800 sqm and is equipped with 20 fume hoods. This facility focuses on lifecycle management, backward integration, new product development, and CMO/CDMO opportunities
2. The Ambernath R&D lab is now fully operational, supporting the next phase of the
company’s expansion and innovation strategy.
• These centres will help to develop identified APIs which will complement existing product
profile
• The controlled drugs portfolio is set to be expanded, with potential APIs already identified and currently in the development pipeline. Additionally, the company is evaluating product portfolio expansion by selecting new products in the anti-diabetic and anesthetic segments.
•
Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products as per their needs
• We have recently announced one of our key CMO project with a leading European company where we will be exclusive API supplier. The contract spans a period of 10 years and is expected to generate peak revenue of INR 60 crs/year starting from FY27
•
In addition to the aforementioned contract, the company has identified two similar opportunities in the API and advanced intermediate space, along with several other potential opportunities.
New markets
Capacity enhancement
• Company is currently doing business with over 1500+ customers and has presence in more
• Commissioned State-of-the-Art Module E Production Block at Lote Parshuram, boosting
than 120+ countries
our capacity by over 55%, increasing it from 597 KLPD to 932 KLPD
• The geographical locations are distributed within sales team to focus on sustaining the
business and expansion through new customer acquisition
• For regulated market, regulatory team is registering the products and filling DMFs. Sales team is in discussion with new customers to qualify us as a reliable source and started sending samples and supplying APIs for their product validation
• Company has taken additional steps for business expansion around the globe especially in
North America, Japan, Australia and New Zealand.
Q4 FY25 Earnings Presentation
• Capacity enhancement for further backward integration of existing products, new product
rollouts and CMO/CDMO opportunities
• We are developing a new formulation facility in Ambernath, along with an R&D facility
dedicated to the development of innovative products.
32
Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com
Ernst & Young LLP
Runjhun Jain +91 98207 20993 runjhun.jain1@in.ey.com
Sneha Salian +91 98194 30437 sneha2.salian@in.ey.com
THANK YOU